Tumor Clinical Trials in New York, New York
223 recruitingNew York, New York
Showing 1–20 of 223 trials
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 1Phase 2
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company880 enrolled66 locationsNCT05768139
Recruiting
Phase 1Phase 2
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Locally Advanced Solid Tumor
Tango Therapeutics, Inc.225 enrolled26 locationsNCT05732831
Recruiting
Phase 1
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Phase 1
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+1 more
Cogent Biosciences, Inc.100 enrolled6 locationsNCT07361562
Recruiting
Phase 1
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Breast NeoplasmsEsophageal AdenocarcinomaMesothelin Positive+5 more
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT06623396
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Breast CancerUrothelial CarcinomaSoft Tissue Sarcoma+2 more
Avacta Life Sciences Ltd158 enrolled9 locationsNCT04969835
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
Phase 1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
MOMA Therapeutics220 enrolled18 locationsNCT06545942
Recruiting
Phase 1Phase 2
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Advanced Solid TumorHigh Grade Serous Adenocarcinoma of OvarySquamous Non-small-cell Lung Cancer
Volastra Therapeutics, Inc.200 enrolled14 locationsNCT05902988
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Exelixis429 enrolled16 locationsNCT05932862
Recruiting
Phase 1Phase 2
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Solid Tumors
ORIC Pharmaceuticals350 enrolled42 locationsNCT05315700
Recruiting
Phase 1
Brodalumab in the Treatment of Immune-Related Adverse Events
Breast CancerLiver CancerEsophageal Cancer+15 more
Brian Henick, MD11 enrolled1 locationNCT06673329